Port-Site Metastasis in Gynecological Malignancies

Benabou, K.; Khadraoui, Wafa; Khader, Tarek; Hui, Pei; Fernández, Rodrigo; Azodi, Masoud; Menderes, Gulden

doi:10.4293/jsls.2020.00081

Cited by 6 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The management of port site metastasis is often individualised and is dependent on the distribution of the disease, presence of other metastasis, and patient fitness to undergo further treatment. Options include radical excision alone or in combination with adjuvant chemotherapy and abdominal wall irradiation [16]. Benabou et al describe a comparable case of laparoscopically managed FIGO Stage 1B1 endocervical adenocarcinoma where the patient also underwent clinical surveillance [16].…”

Section: Discussionmentioning

confidence: 99%

“…Options include radical excision alone or in combination with adjuvant chemotherapy and abdominal wall irradiation [16]. Benabou et al describe a comparable case of laparoscopically managed FIGO Stage 1B1 endocervical adenocarcinoma where the patient also underwent clinical surveillance [16]. Abdominal wall recurrence was diagnosed after 4 years and this was also near the prior assistant port site; a port which was used for removal of lymph nodes in a laparoscopic bag [16].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Surgical Management of Oligometastatic Port Site Recurrence Following Robotic Assisted Gynaecological Cancer Surgery: A Case Report

Homer,

Abdul-Aziz,

Babu

2024

J. Can. Tumor Int.

View full text Add to dashboard Cite

Aims: Port site recurrence is a rare complication of laparoscopic or robotic surgery for gynaecological cancer. The exact mechanism is not well understood and there are few cases detailing this phenomenon specifically after robotic assisted surgery for gynaecological cancer. The aim of this case report is to demonstrate how an oligometastatic port site recurrence can be managed following robotic surgery for cervical carcinoma. Presentation of Case and Discussion: The authors present a case of oligometastatic port site metastasis in a 49-year-old woman with Stage 1B1 grade 2 endocervical adenocarcinoma following primary robotic radical hysterectomy with lymph node dissection. The recurrence was diagnosed 16 months post primary surgery in the anterior abdominal wall and the lung. Both were resected with clear margins and the patient continued follow up. A further second ipsilateral port site recurrence was diagnosed 81 months after the initial surgery, this was also excised and the abdominal wall reconstructed with mesh. The patient is asymptomatic and disease-free 7.5 years after her initial diagnosis. Conclusion: Oligometastatic port site recurrence can be successfully managed by surgical excision in selected cases, however more research is required to develop better understanding of the mechanisms and risk factors for port site metastasis in different gynaecological cancers which would in turn help to improve clinical decision making.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Surgical Management of Oligometastatic Port Site Recurrence Following Robotic Assisted Gynaecological Cancer Surgery: A Case Report

Homer,

Abdul-Aziz,

Babu

2024

J. Can. Tumor Int.

View full text Add to dashboard Cite

show abstract

“…Port site metastasis is a concern in particular in patients with advanced ovarian carcinoma (incidence up to 17% (Vergote et al, 2005)). It is unclear whether direct contamination by tumour cells or secondary effects from pneumoperitoneum cause this complication (Benabou et al, 2021;Ost et al, 2005) and the possible protective role of port-site excision has not been clarified (Lago et al, 2019). High-quality data on impact of port site metastasis on the prognosis are scarce, however the available data suggest lacking impact on survival (Ataseven et al, 2016).…”

Section: Special Issues Regarding Mis In Gynaecological Cancermentioning

confidence: 99%

The role of minimally invasive surgery in gynaecological cancer: an overview of current trends

Balafoutas,

Vlahos

2024

Facts Views Vis ObGyn

View full text Add to dashboard Cite

Background: The capabilities of minimally invasive surgery, either as conventional laparoscopy, or as robotic surgery, have increased to an extent that it enables complex operations in the field of gynaecological oncology. Objective: To document the role of minimally invasive gynaecological surgery in cancer. Materials and Methods: A review of the literature that shaped international guidelines and clinical practice. Main outcomes measures: Current guidelines of major international scientific associations and trends in accepted clinical practice. Results: In recent years, evidence on oncologic outcome has limited the role of minimally invasive techniques in cervical cancer, while the treatment of early endometrial cancer with laparoscopy and robotic surgery has become the international standard. In ovarian cancer, the role of minimally invasive surgery is still limited. Current evidence on perioperative morbidity underlines the necessity to implicate minimally invasive techniques whenever possible. Conclusion: The optimal surgical route for the treatment of gynaecological cancer remains in many cases controversial. The role of minimally invasive surgery remains increasing in the course of time. What is new? This comprehensive review offers an entire perspective on the current role of minimally invasive surgery in gynaecological cancer therapy.

show abstract

“…Other possible advantages and disadvantages of all three surgical approaches are shown in Supplementary Figure 1, http://links.lww.com/COON/A34 [10]. Disadvantages of RALS are the impossibility of manual palpation of lymph nodes and the possible risk of trocar side metastasis and the costs [11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Robot-assisted laparoscopic staging compared to conventional laparoscopic staging and laparotomic staging in clinical early stage ovarian carcinoma

Bouter

Lok

Trum

2022

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewRobot-assisted laparoscopic staging (RALS) is increasingly used for staging epithelial ovarian cancer (EOC). Evidence of its safety is limited. The aim of this review is to compare the efficacy and safety of RALS in clinical early-stage EOC to conventional laparoscopy and laparotomy and to assess the level of evidence that is currently available to adopt this surgical technique. Recent findingsOnly retrospective studies comparing staging by minimally invasive surgery (MIS) to laparotomy are available. Both RALS and conventional laparoscopic staging shorten length of hospital stay (LHS, mean -2.9 days) and decrease estimated blood loss (EBL, mean -79 ml less) compared to laparotomy. Complication rates and number of lymph nodes collected are similar in all surgical staging techniques. Survival outcomes after staging by MIS cannot be compared to staging by laparotomy because of the lack of evidence but RALS is probably noninferior to conventional laparoscopic staging. SummaryRALS probably improves perioperative outcomes in patients with clinical early stage EOC similar to conventional laparoscopic staging. Whether oncologic outcomes of RALS are comparable to open and conventional approaches is uncertain as there is only level C evidence and randomized controlled trials are urgently needed to confirm the current retrospective findings.

show abstract

Port-Site Metastasis in Gynecological Malignancies

Cited by 6 publications

References 39 publications

Surgical Management of Oligometastatic Port Site Recurrence Following Robotic Assisted Gynaecological Cancer Surgery: A Case Report

Surgical Management of Oligometastatic Port Site Recurrence Following Robotic Assisted Gynaecological Cancer Surgery: A Case Report

The role of minimally invasive surgery in gynaecological cancer: an overview of current trends

Robot-assisted laparoscopic staging compared to conventional laparoscopic staging and laparotomic staging in clinical early stage ovarian carcinoma

Contact Info

Product

Resources

About